$5.83
0.437.96%
Últ. Act.: Nov 6, 4:42 PM
Cytek Biosciences (CTKB) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $-0.05 | $-0.07 | 28.6 % |
| Q2 | Aug 5, 2026 | $-0.09 | $-0.02 | -350.0 % |
| Q1 | May 7, 2026 | $-0.15 | $-0.09 | -66.7 % |
| Q4 | Feb 26, 2026 | $-0.34 | $-0.01 | -3300.0 % |
Quarterly Revenue (Billions)
Cytek Biosciences (CTKB) publicó su última previsión de noviembre 4, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $208M - $211M para el período.
En comparación con la previsión anterior, Cytek Biosciences mantenido redujo su previsión de ingresos desde un rango anterior de $207M - $212M.
Cytek Biosciences ha emitido 23 actualizaciones de orientación entre el noviembre 9, 2022 y el noviembre 4, 2026. During this period, the company raised its outlook 5 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.07 | $-0.02 | $-0.09 | $-0.01 |
| Actual | $-0.05 | $-0.09 | $-0.15 | $-0.34 |
| Surprise | +28.6% | -350.0% | -66.7% | -3300.0% |
| Revenue | ||||
| Estimate | $52.9M | $48.5M | $44.2M | $58.8M |
| Actual | $53.2M | $48.1M | $44.1M | $62.1M |
| Surprise | +0.55% | -0.81% | -100.0% | +5.68% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.02 | $-0.12 | $-0.08 | $-0.07 |
| Revenue | ||||
| Consensus | $63.7M | $48.3M | — | — |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $53.23M | $52.94M | 0.55 % |
| Q2 | Aug 5, 2026 | $48.14M | $48.53M | -0.81 % |
| Q1 | May 7, 2026 | $44.14M | $44.22M | -100.0 % |
| Q4 | Feb 26, 2026 | $62.14M | $58.80M | 5.68 % |